Board of Directors

Alexis Borisy, Chairman of the Board of Directors, Co-founder, Foundation Medicine and Partner at Third Rock Ventures

Alexis Borisy is a successful biotechnology entrepreneur with 20 years of experience building and operating innovative science-based organizations. Mr. Borisy joined the life sciences venture capital firm Third Rock Ventures in 2009 to focus on the formation, development and strategy of new companies. He co-founded Foundation Medicine and served as the company’s interim CEO through May 2011.

Prior to joining Third Rock Ventures, Mr. Borisy founded CombinatoRx in 2000, serving as its Chief Executive Officer and bringing the company public on the NASDAQ. He has raised $750 million in financing and business development deals, and has authored numerous scientific papers and patents. Trained in chemistry and chemical biology at Harvard where he was a Howard Hughes Predoctoral Fellow, Mr. Borisy was honored as the Massachusetts Institute of Technology’s Technology Review Innovator of the Year. He was also chosen as the New England Entrepreneur of the Year in Life Sciences and was honored as a Presidential Scholar.

Mr. Borisy’s undergraduate degree in chemistry is from the University of Chicago, and he did his graduate work in the laboratory of Dr. Stuart Schreiber at Harvard University. Mr. Borisy serves on the Board of the Biotechnology Industry Organization, is an Overseer at the Boston Museum of Science, is the Chairman of Forma Therapeutics, and serves on the board of Blueprint Medicines.


Brook Byers, Investment Partner, Kleiner Perkins Caufield & Byers

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than sixty new technology based ventures, many of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. Mr. Byers was the founding President and then Chairman, of four biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is currently on the Board of Directors of ten companies, most recently joining CardioDX, Crescendo, Genomic Health, Five Prime, OptiMedica, Pacific Biosciences, Tethys, Veracyte and XDx.

Mr. Byers was President and a Director of the Western Association of Venture Capitalists. He is a currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford’s Bio-X Advisory Council and the Stanford Eye Council. He was Co-Chair of the five year, $1.4 billion, UCSF Capital Campaign. In 2007, he was awarded the “UCSF Medal” as their honorary degree equivalent. In 2008, he was elected a Fellow of the American Academy of Arts and Sciences. In 2009, he received the Lifetime Achievement Award from the National Venture Capital Association. In May, 2010, he received an Honorary Ph.D. from Georgia Tech.

Raised in Atlanta, Georgia, Mr. Byers graduated in Electrical Engineering from Georgia Tech and received an MBA from Stanford.

Evan Jones, Managing Member of jVen Capital, LLC

Evan Jones, has over two decades of operating and investment experience in the life sciences industry where he has founded or helped start numerous life sciences companies. As co-founder and CEO of Digene Corporation (acquired by QIAGEN in 2007), a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing, Evan was deeply involved in commercializing and bringing public awareness to the first molecular test for human papillomavirus, which made possible early detection of cervical cancer and dramatically reduced mortality for this cancer. Evan served as Chief Executive Officer of Digene Corp from 1990 to 2006. From 1988 to September 1990, he served as President of Neomorphics, Inc.

Mr. Jones is a member of the board of directors of CAS Medical Systems, Inc., a developer of patient vital signs monitoring products and technologies, and Veracyte, Inc., a private venture-backed company developing molecular tests to improve the diagnostic accuracy of cytology samples. Mr. Jones is also a member of the board of directors of the Children’s National Medical Center and the Children’s Research Institute in Washington, D.C. He is chairman of the Campaign for Public Health Foundation, an independent, not-for-profit organization dedicated to increasing funding for the Centers for Disease Control and Prevention and is a member of the board of directors and the Executive Committee of Research!America, a not-for-profit public education and advocacy alliance.

Mr. Jones received a B.A. degree from the University of Colorado and an M.B.A. degree from The Wharton School at the University of Pennsylvania.

Mark Levin, Partner at Third Rock Ventures

Mark Levin is an industry visionary with more than 36 years of experience, including 25 years building and operating leading biotech companies. Mr. Levin co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of its portfolio companies, as well as actively identifying and evaluating new investments. He also assumes active leadership roles in its portfolio companies, functioning as Chief Executive Officer through the first 12-18 months post launch.

Mr. Levin was Co-founder of Mayfield Fund's life sciences effort where he was also the founding Chief Executive Officer of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals. Mr. Levin served as Chief Executive Officer of Millennium Pharmaceuticals for 12 years. Earlier in his career, Mr. Levin was a scientist at Lilly and Genentech.

Mr. Levin holds an M.S. in Chemical and Biomedical Engineering from Washington University. He is a member of the National Academy of Engineering and the Friends of Personalized Medicine, and also co-founded upSTART in Cambridge, Mass.


Michael J. Pellini, M.D., President and Chief Executive Officer

Dr. Pellini joined Foundation Medicine as President and Chief Executive Officer in May 2011, bringing a breadth of experience in life sciences and the clinical diagnostics and laboratory industries to the company. Dr. Pellini came to Foundation Medicine from Clarient, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Dr. Pellini joined GE Healthcare through the integration of Clarient, Inc., where he worked with the company’s leadership team to drive critical regulatory and reimbursement strategies in parallel with the development and commercialization of multiple diagnostic tests. Dr. Pellini’s leadership was instrumental in building Clarient to the highly successful acquisition by GE Healthcare in October 2010.

Prior to his tenure with Clarient, Dr. Pellini served as Vice President, Life Sciences at Safeguard Scientifics, Inc. where he leveraged his business and medical expertise to explore new market opportunities and to support Safeguard’s partner companies. Prior to Safeguard, he was Executive Vice President and Chief Operating Officer at Lakewood Pathology Associates, a national molecular and pathology services company, which was acquired by Water Street Healthcare Partners in 2006. Prior to that, Dr. Pellini was an Entrepreneur-in-Residence at BioAdvance, where he was responsible for reviewing and evaluating early-stage life science companies. He also served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004.

Dr. Pellini received a B.A. from Boston College, an M.B.A. from Drexel University and an M.D. from Jefferson Medical College of Thomas Jefferson University. Dr. Pellini serves as a member the Boston College Technology Council, the Executive Committee of the Jefferson Medical College Alumni Association, and the Board of Trustees for the Coriell Institute of Medical Research.


David Schenkein, M.D., Chief Executive Officer, Agios Pharmaceuticals

David Schenkein joined Agios Pharmaceuticals in August 2009 as the Chief Executive Officer. Prior to joining Agios, Dr. Schenkein was the Senior Vice President, Clinical Hematology/Oncology at Genentech, Inc. in San Francisco where he was responsible for leading the medical and scientific strategies for their BioOncology portfolio. He has been a Medical Oncologist and Hematologist for over 20 years and while in San Francisco was an Adjunct Clinical Professor of Medicine Oncology at Stanford University School of Medicine.

Prior to joining Genentech, Dr. Schenkein spent 17 years in academic and clinical medicine as an attending physician in Hematology Oncology at the Tufts-New England Medical Center in Boston, where he was an associate professor and held the position of director of the Cancer Center. From 2001- 2006, he worked at Millennium Pharmaceuticals where he served as the Senior Vice President of Clinical Research, overseeing the clinical development of Velcade, a first-in class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. Dr. Schenkein holds a B.A. in Chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School.


Krishna Yeshwant, M.D., Partner, Google Ventures

Dr. Krishna Yeshwant is a physician, programmer, and entrepreneur who has been working with Google Ventures since its inception.

Prior to Google, he helped start an electronic data interchange company that was acquired by Hewlett-Packard (HP) and a network security company that was acquired by Symantec (SYMC). He also co-authored the business plan for Diagnostics For All, which won both the Harvard Business School and MIT $100k business plan competitions.

Previously, Krishna published several book chapters and journal articles in the field of computer guided surgery, completed research in tissue engineering, and developed and licensed multiple surgical devices. He has worked with the technology transfer offices of MIT, Harvard, and Massachusetts General Hospital.

Krishna has a B.S. in Computer Science from Stanford University. He also earned an M.D. from Harvard Medical School and an M.B.A. from Harvard Business School.